2025
Simultaneous Symmetrizing Surgery on the Contralateral Breast in Unilateral Autologous Breast Reconstruction Is Cost-Effective
Zhao K, Kammien A, Graetz E, Moore M, Evans B, Schneider E, Ayyala H. Simultaneous Symmetrizing Surgery on the Contralateral Breast in Unilateral Autologous Breast Reconstruction Is Cost-Effective. Journal Of Reconstructive Microsurgery 2025 PMID: 39821138, DOI: 10.1055/a-2517-0803.Peer-Reviewed Original ResearchFree flap reconstructionSymmetrization surgeryFlap reconstructionBreast reconstructionDelayed reconstructionPatient characteristicsSingle-stage breast reconstructionUnilateral autologous breast reconstructionAutologous breast reconstructionSurgical site infectionThirty-day complicationsContralateral breastUnilateral reconstructionImmediate reconstructionSite infectionWound dehiscenceThirty-dayIncreased complicationsNational administrative dataSurgeryRevision surgeryComplicationsPatientsWilcoxon testChi-square
2023
SLAM-based Surgical Guidance For Breast Reconstruction Surgery
Fu E, Alarcón de la Lastra Á, Zhou H, Zhang R, Broyles J, Ayyala H, Pomahac B, Jayender J. SLAM-based Surgical Guidance For Breast Reconstruction Surgery. 2023, 1-2. DOI: 10.31256/hsmr2023.1.Peer-Reviewed Original Research
2020
Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI
Li W, Onishi N, Newitt D, Harnish R, Jones E, Wilmes L, Gibbs J, Price E, Joe B, Chien A, Berry D, Boughey J, Albain K, Clark A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yee D, Yung R, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Yau C, Asare S, DeMichele A, Goudreau S, Abe H, Sheth D, Wolverton D, Fountain K, Ha R, Wynn R, Crane E, Dillis C, Kuritza T, Morley K, Nelson M, Church A, Niell B, Drukteinis J, Oh K, Jafarian N, Brandt K, Choudhery S, Bang D, Mullins C, Woodard S, Zamora K, Ojeda-Fornier H, Eghedari M, Sheth P, Hovanessian-Larsen L, Rosen M, McDonald E, Spektor M, Giurescu M, Newell M, Cohen M, Berman E, Lehman C, Smith W, Fitzpatrick K, Borders M, Yang W, Dogan B, Esserman L, Hylton N. Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI. Cancer Research 2020, 80: p6-02-01-p6-02-01. DOI: 10.1158/1538-7445.sabcs19-p6-02-01.Peer-Reviewed Original ResearchEffect of background parenchymal enhancementFunctional tumor volumeBackground parenchymal enhancementLower background parenchymal enhancementNeoadjuvant chemotherapyTumor volumeParenchymal enhancementDynamic contrast-enhancedHR-/HER2Treatment time pointsContralateral breastPatient cohortTime pointsHigher background parenchymal enhancementI-SPY 2 TRIALWeeks of neoadjuvant chemotherapyLocally advanced breast cancerMRI examsHormone receptorsHR-/HER2- subtypeMR tumor volumesPrediction of pCRNeoadjuvant chemotherapy regimensEnhancement thresholdHR-/HER2+
2013
3.0 Tesla vs 1.5 Tesla breast magnetic resonance imaging in newly diagnosed breast cancer patients
Butler RS, Chen C, Vashi R, Hooley RJ, Philpotts LE. 3.0 Tesla vs 1.5 Tesla breast magnetic resonance imaging in newly diagnosed breast cancer patients. World Journal Of Radiology 2013, 5: 285-294. PMID: 24003354, PMCID: PMC3758496, DOI: 10.4329/wjr.v5.i8.285.Peer-Reviewed Original ResearchPositive predictive valueHigh positive predictive valueBreast cancer patientsSuspicious lesionsT groupAdditional malignanciesT MR examinationsCancer patientsAdditional cancersBreast cancerExact testAccountability Act-compliant retrospective reviewMR examinationsInstitutional review board approvalBreast magnetic resonanceFisher's exact testMR imaging studiesReview board approvalNeoadjuvant chemotherapyIndex cancerContralateral breastRetrospective reviewT MR imagingBiopsy resultsPathologic diagnosis
2011
Characteristics of multifocal and multicentric breast cancers detetected by preoperative MRI.
Killelea B, Grube B, Philpotts L, Sowden M, Horowitz N, Lannin D. Characteristics of multifocal and multicentric breast cancers detetected by preoperative MRI. Journal Of Clinical Oncology 2011, 29: 67-67. DOI: 10.1200/jco.2011.29.27_suppl.67.Peer-Reviewed Original ResearchBreast cancer patientsSecond tumorPreoperative MRISecond malignanciesPR statusCancer patientsBreast cancerER/PR statusMulticentric breast cancerSuspicious MRI findingsNumber of patientsDiagnosis of cancerLobular histologyNodal statusContralateral breastMRI findingsNode positiveTumor characteristicsTumor sizeHER2 statusAdditional tumorsSecondary lesionsSecondary tumorsPatientsControl group
2009
Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy.
Pierce L, Phillips K, Griffith K, Buys S, Gaffney D, Moran M, Haffty B, Ben-David M, Garber J, Merajver S, Balmanya J, Meirovitz A, Domchek S. Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy. Cancer Research 2009, 69: 959-959. DOI: 10.1158/0008-5472.sabcs-09-959.Peer-Reviewed Original ResearchContralateral breast cancerOperable breast cancerBreast conservationBreast cancerLocal therapyBRCA1/2 mutationsDistant failureClinical characteristicsBRCA1/2 carriersLocal failureBC-specific survivalDeleterious BRCA1/2 mutationsLocal treatment optionsInvasive lobular cancerGermline BRCA1/2 mutationsSignificant predictorsSignificant differencesOnly significant predictorAdjuvant chemotherapyBCT patientsOverall survivalContralateral breastLobular cancerLocal recurrenceRandomized trialsThe Yale University Experience of Early‐Stage Invasive Lobular Carcinoma (ILC) and Invasive Ductal Carcinoma (IDC) Treated with Breast Conservation Treatment (BCT): Analysis of Clinical‐Pathologic Features, Long‐Term Outcomes, and Molecular Expression of COX‐2, Bcl‐2, and p53 as a Function of Histology
Moran MS, Yang Q, Haffty BG. The Yale University Experience of Early‐Stage Invasive Lobular Carcinoma (ILC) and Invasive Ductal Carcinoma (IDC) Treated with Breast Conservation Treatment (BCT): Analysis of Clinical‐Pathologic Features, Long‐Term Outcomes, and Molecular Expression of COX‐2, Bcl‐2, and p53 as a Function of Histology. The Breast Journal 2009, 15: 571-578. PMID: 19995377, DOI: 10.1111/j.1524-4741.2009.00833.x.Peer-Reviewed Original ResearchConceptsBreast conservation treatmentInvasive lobular carcinomaInvasive ductal carcinomaEarly-stage invasive lobular carcinomaClinical-pathologic featuresContralateral breast cancerCOX-2Breast relapseILC patientsDuctal carcinomaBreast cancerER/PR/HERBcl-2Cause-specific survivalLong-term outcomesTriple-negative tumorsChemo-preventive strategiesYears of ageImmuno-histochemical analysisExpression of p53Function of histologyDistant relapseInvasive lobularNodal statusContralateral breast
2003
Follow-up care of breast cancer survivors
Partridge AH, Winer EP, Burstein HJ. Follow-up care of breast cancer survivors. Seminars In Oncology 2003, 30: 817-825. PMID: 14663782, DOI: 10.1053/j.seminoncol.2003.08.026.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsBreast cancerCancer survivorsPossible long-term complicationsSecond primary breast cancerComplications of therapyPrimary breast cancerLong-term complicationsLocal-regional recurrenceSymptoms of recurrenceBreast cancer treatmentPatient-clinician relationshipMetastatic diseaseContralateral breastPsychosocial concernsPsychosocial supportAdequate surveillanceCancer treatmentCancerComplicationsPatientsPersonal historyRecurrenceTherapySurvivorsA comparative dosimetric study on tangential photon beams, intensity-modulated radiation therapy (IMRT) and modulated electron radiotherapy (MERT) for breast cancer treatment
Ma C, Ding M, Li JS, Lee MC, Pawlicki T, Deng J. A comparative dosimetric study on tangential photon beams, intensity-modulated radiation therapy (IMRT) and modulated electron radiotherapy (MERT) for breast cancer treatment. Physics In Medicine And Biology 2003, 48: 909-924. PMID: 12701895, DOI: 10.1088/0031-9155/48/7/308.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiation therapyTangential photon beamsContralateral breastBreast cancerRadiation therapyTreatment planMaximum doseBreast cancer treatmentTreatment optimizationComparative dosimetric studyBreast treatment plansPhoton treatment plansPhoton beamsElectron radiotherapySuperficial targetsMultiple beam anglesLungMedium dosesDose conformityTangential beamsNormal tissuesCancer treatmentMERT plansIMRT plansMV photon beam
2000
Modulated Electron Beams for Treatment of Breast Cancer
Ma C, Pawlicki T, Lee M, Jiang S, Li J, Deng J, Yi B, Mok E, Boyer A. Modulated Electron Beams for Treatment of Breast Cancer. 2000, 173-175. DOI: 10.1007/978-3-642-59758-9_64.Peer-Reviewed Original ResearchContralateral breastBreast cancer treatmentChest wall treatmentSuch conventional treatmentHigh-dose volumeTangential photon fieldsTumor locationBreast cancerSecondary cancersEffective modalityRadiation therapyLow doseConventional treatmentNormal tissuesCancer treatmentPatient sizeMajor causeLungDoseTreatmentNormal structureCancerBreastHeartScatter dose
1992
The Genetic Epidemiology of Second Primary Breast Cancer*
Bernstein J, Thompson W, Risch N, Holford T. The Genetic Epidemiology of Second Primary Breast Cancer*. American Journal Of Epidemiology 1992, 136: 937-948. PMID: 1456270, DOI: 10.1093/oxfordjournals.aje.a116566.Peer-Reviewed Original ResearchConceptsSecond primary breast cancerPrimary breast cancerContralateral breast cancerFirst primary breast cancerFirst-degree relativesBreast cancerFamily historyOvarian cancerMulti-center population-based case-control studyPopulation-based case-control studyAge-adjusted rate ratioSteroid Hormone StudyBilateral breast cancerEnd Results ProgramRate ratioCase-control studyCorresponding rate ratiosContralateral breastEndometrial cancerProspective studyResults ProgramSecond primaryCohort membersHigh riskHormone Study
1981
Risk of subsequent contralateral breast carcinoma in a population of patients with in‐situ breast carcinoma
Webber B, Heise H, Neifeld J, Costa J. Risk of subsequent contralateral breast carcinoma in a population of patients with in‐situ breast carcinoma. Cancer 1981, 47: 2928-2932. PMID: 6266644, DOI: 10.1002/1097-0142(19810615)47:12<2928::aid-cncr2820471232>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsBreast carcinomaContralateral carcinomaSubsequent cancerContralateral breast carcinomaMajority of patientsPopulation of patientsSecond breast cancerNoninvasive breast carcinomaSitu breast carcinomaContralateral tumorsOverall survivalContralateral breastHistological typeSurvival figuresLobular carcinomaOpposite breastBreast cancerSitu carcinomaCarcinomaS. womenCancerPatientsBreastWomenMastectomy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply